FierceBiotech16h
Gilead's Daniel O'Day relishes Dietmar Berger reunion as cancer specialist agrees to join from Sanofi
Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...
BioPharma Dive7h
Dietmar Berger is Gilead’s new CMO; Padlock investors sue Bristol Myers
Gilead CEO Daniel O’Day has hired Berger away from Sanofi. Elsewhere, Lonza is reorganizing and Bausch + Lomb is exploring a ...
ENDPOINTS NEWS14h
Gilead names Di­et­mar Berg­er CMO as it eyes R&D re­set
Gilead Sciences names Sanofi's Dietmar Berger as new CMO, replacing Merdad Parsey amid challenging year marked by setbacks ...
The Pharma Letter13h
Gilead Sciences names new CMO
US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...
The American Journal of Managed Care2d
Rare Blood Disease Innovations Address Unmet Needs, According to ASH Data
Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & ...
GlobalData on MSN4d
Sanofi’s Phase III trial of rilzabrutinib for thrombocytopenia meets endpoint
Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune ...
HSBC eyes $3 bln in potential savings from overhaul, Bloomberg News reports
HSBC Holdings Plc is examining plans that could cut costs by at least $3 billion as the bank continues to restructure its ...
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patientsNew analysis from the IMROZ phase 3 ...